The approval of Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound has marked a significant shift in the treatment of obesity, but experts now face new challenges in determining who should receive these life-changing medications.
With 57 million working-age Americans and nearly 14 million retirement-age Americans meeting the criteria for these drugs, their vast market potential is undeniable. However, opinions among physicians vary on whether everyone eligible should be treated, with some advocating for a blanket approach while others draw distinctions between those at risk of or already experiencing weight-related health complications.
As shortages and high prices force doctors to prioritize patients, an international committee of obesity experts will release an interim report in 2025 that aims to provide evidence-backed criteria for diagnosing “clinical” obesity. This move seeks to help doctors better define who the right candidate is for GLP-1s, distinguishing between those with the true disease and those who gained weight without health complications.
The development of these guidelines could lead to a more critical assessment of the connection between weight and health, making treatment more equitable and facilitating coverage through insurers. However, this raises questions about when someone’s weight loss is enough, as well as the need for ongoing treatment and the potential risks associated with muscle mass loss and nutrient intake.
Experts acknowledge that establishing clear goals and guidelines for obesity treatment will be crucial in navigating these complexities. As data becomes the best guide, doctors will continue to feel their way through this new era, weighing the benefits of GLP-1s against the need for more nuanced approaches.
Source: https://www.adn.com/opinions/national-opinions/2024/12/25/opinion-weve-accepted-wegovy-and-zepbound-the-next-phase-is-harder